null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

Near-zero debt; micro-cap with minimal long-term liabilities; 20% rate rise has negligible P&L impact given <$500K total debt estimated.

Minimal interest rate sensitivity; company is effectively debt-free and self-funds via equity raises; rate changes affect cost of future equity dilution.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Primary chokepoints: (1) Canadian pharmacy network consolidation risk; (2) Abbott/Roche diagnostic device manufacturing in Asia-Pacific.

Revenue is ~100% Canadian CAD-denominated; no material sovereign currency devaluation exposure; international expansion not yet underway.

Operations entirely within Canada; single-currency (CAD) exposure; no material forex risk from international markets at current stage.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on Shoppers Drug Mart/Loblaw pharmacy network as primary distribution channel; likely exceeds 30% of operational throughput.

SaaS/data-services platform (HealthTab); cloud disruption would require 30-90 day replatforming but core pharmacy relationships would persist.

Pharmacy-as-a-service data aggregator; secondary model is health data licensing to pharma/payers; not solely cloud-dependent for revenue continuity.

Moderate API coupling risk; HealthTab integrates with pharmacy POS and lab systems; switching costs are real but not insurmountable for large pharmacy chains.

Low Howey risk; revenue model is fee-for-service and SaaS licensing; no tokenized instruments or profit-sharing structures identified.

Very High

Moderate risk; handles Canadian patient health data under PIPEDA/provincial health privacy laws; limited GDPR/CCPA exposure given Canada-only operations.

Low antitrust risk; small market share in pharmacy diagnostics; no dominant position; operates as enabling infrastructure rather than market gatekeeper.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Primarily recurring SaaS/platform fees estimated at ~60-70% of revenue; remainder transactional per-test fees; multi-year pharmacy contracts provide revenue visibility.

Per-test data capture fees plus platform licensing to pharmacies; secondary monetization via anonymized health data licensing to pharmaceutical companies.

Per-test + monthly SaaS hybrid pricing; vulnerable if large pharmacy chains renegotiate volume discounts; limited pricing power against Loblaw's scale.

Low-to-moderate pricing power; dependent on pharmacy chain goodwill; differentiated by point-of-care data network but faces margin pressure from large customers.

Estimated gross margins 50-65%; software/data layer is high-margin but hardware/diagnostic component dilutes blended margin toward mid-range SaaS benchmarks.

Low free-rider risk; platform access requires contractual agreement; however, pharmacy chains could internalize capability, representing indirect churn threat.

Revenue growth is sublinear to headcount; platform model allows significant pharmacy network scaling without proportional staff increases; estimated 3:1 revenue/headcount leverage.

Marginal cost of adding pharmacy locations is low (software onboarding); primary variable cost is customer success and regulatory compliance, not production.

Not a franchise model; however, pharmacy network compliance with HealthTab protocols varies; regulatory drift risk under provincial health authority oversight is moderate.

At 10x scale, CAC likely declines via network referrals among pharmacy chains; LTV/CAC ratio should improve significantly given fixed platform development costs.

Moderate data network effect; more pharmacy locations generate richer longitudinal health datasets, increasing value to pharma/payer customers; not yet at critical mass.

AI displacement risk is low-to-moderate; AI could enhance data analytics layer but core value is physical point-of-care network, which AI cannot easily replicate.

Moderate recession resistance; pharmacy-based diagnostics are semi-essential health services; however, discretionary testing volumes may decline in deep recessions.

Retail pharmacy chains (Shoppers Drug Mart/Loblaw dominant); high customer concentration risk with likely >50% revenue from single pharmacy group.

Pharmaceutical companies and health data buyers as secondary segment; diversification benefit but early-stage with limited contracted revenue from this cohort.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed toward HealthTab platform expansion and pharmacy network onboarding; minimal legacy infrastructure drag; forward-looking capex allocation confirmed.

0001355736

AVCRF